Quick Overview

BULLET POINTS:

• AI-driven, EEG-centered mental healthcare platform for early detection, treatment, and telemedicine services for Alzheimer's disease dementia and other neuropsychiatric disorders.
• The Seoul-based company was founded in 2012 as a spin-off of the National Standard Data Center for Korean EEG at Seoul National University.
• iMediSync utilizes proprietary AI technology and a vast normative database of over 1,300 healthy subjects to power neuropsychiatric research and treatment worldwide.
• The company has FDA approval and offers comprehensive services for various neuropsychiatric conditions.
• iMediSync is at the forefront of revolutionizing mental healthcare by providing personalized, cutting-edge solutions for early detection, prevention, and treatment of neuropsychiatric disorders.

DESCRIPTION:

iMediSync is revolutionizing the way we approach mental healthcare with its AI-driven, EEG-centered digital platform. With early detection, treatment, and telemedicine services for Alzheimer's disease dementia and other neuropsychiatric disorders, this company is at the forefront of innovation in mental healthcare. iMediSync is built on a foundation of cutting-edge research and technology. With the world's largest age and sex-specific normative database, advanced proprietary AI technology, and a worldwide R&D network, it is poised to transform the way we think about and treat neuropsychiatric conditions. And with FDA approval, you can trust that this platform is safe and effective.